doripenem

Phase 3

Johnson & Johnson (JNJ)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Pneumonia

View Full Landscape

Drug Information

Target Indication

Pneumonia

Clinical Trial

NCT00211003

Last updated: 12/4/2025

Patent & Exclusivity

No Patent DataRLD

Application

NDA 022106

Source: FDA Orange Book

Regulatory Approvals

EMA7/25/2008

Doribax

Doribax is indicated for the treatment of the following infections in adults: nosocomial pneumonia (including ventilator-associated pneumonia); complicated intra-abdominal infections; complicated urinary tract infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain